Welcome to our dedicated page for Krystal Biotech SEC filings (Ticker: KRYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Krystal Biotech filings document formal disclosures for a commercial-stage biotechnology company developing and commercializing genetic medicines. Recent 8-K reports furnish quarterly and annual financial results, VYJUVEK net product revenue updates, Regulation FD clinical materials, FDA-related program updates, and commercial launch information for VYJUVEK in Japan.
The company's proxy materials disclose board and shareholder-vote matters, executive compensation, equity awards, ownership information, and governance practices. Together, the filings record how Krystal reports operating performance, capital resources, pipeline and regulatory disclosures, and public-company governance for its HSV-1-based gene therapy platform.
Krystal Biotech (KRYS) 10-Q – Q2 2025 highlights
- Revenue: VYJUVEK® drove net product revenue to $96.0 m (+37% YoY); H1 2025 revenue reached $184.2 m (+60%).
- Profitability: Gross margin held at 93%. Income from operations leapt to $39.3 m (vs $8.6 m), thanks to higher sales and the absence of 2024 litigation charges. Net income was $38.3 m ($1.29 diluted EPS) versus $15.6 m ($0.53).
- Cash & Investments: Cash, cash equivalents and short-term investments rose to $682.0 m; total liquidity including long-term investments is $820.8 m. The company expects current resources to fund operations for ≥12 months.
- Expenses: R&D fell 8% YoY to $14.4 m as manufacturing timing shifted; SG&A climbed 27% to $35.2 m reflecting commercial build-out. No litigation settlement expense this quarter (-$12.5 m YoY).
- Balance sheet: Stockholders’ equity surpassed $1.04 bn. Accounts receivable stood at $111.4 m, with ~78% concentrated in one customer.
- Pipeline progress: Multiple Phase 1/2 studies (KB407 CF, KB408 AATD, KB707 oncology, KB803 & KB801 ophthalmology) are enrolling; first EU & Japan launches of VYJUVEK expected H2 2025.
- Risks: DOJ subpoenas regarding genetic-testing program; outcome unknown. Heavy reliance on single product and customer concentration noted.
Krystal Biotech (KRYS) President of R&D, Director and 10% owner Suma M. Krishnan filed a Form 4 disclosing modest open-market sales executed on 9–10 July 2025 under a Rule 10b5-1 trading plan adopted 12 Sep 2024.
- Shares sold (reporting person): 7,000 common shares at weighted-average prices of $150.14–$151.39.
- Shares sold (spouse): 7,127 shares at $150.07–$151.39 under a separate 10b5-1 plan.
- Total shares disposed: 14,127, representing roughly 0.5% of their combined holdings.
- Remaining ownership: 1,456,711 shares directly; 90,000 via SMK Trust; 50,000 via Krishnan Family Trust; spouse retains 1,525,929 shares.
The transactions slightly reduce insider exposure yet leave the couple with an aggregate stake of about 3.1 million shares, signalling continuing alignment with shareholders. Because the sales were pre-scheduled, they carry limited information about the company’s near-term outlook.
On 30 June 2025, Krystal Biotech (KRYS) filed a Form 4 reporting that independent director Julian S. Gangolli received 5,000 stock options with an exercise price of $137.46 and a 10-year term expiring 30 June 2035. The award vests in 12 equal monthly tranches through June 2026, aligning the director’s incentives with shareholder value over the next year. No common shares were bought or sold, and the grant represents potential dilution of well under 0.1 % of outstanding shares, making it immaterial from a capitalization standpoint.